151 related articles for article (PubMed ID: 16150959)
1. Developing drugs for cognitive impairment in schizophrenia.
Breier A
Schizophr Bull; 2005 Oct; 31(4):816-22. PubMed ID: 16150959
[TBL] [Abstract][Full Text] [Related]
2. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia.
Floresco SB; Geyer MA; Gold LH; Grace AA
Schizophr Bull; 2005 Oct; 31(4):888-94. PubMed ID: 16079387
[TBL] [Abstract][Full Text] [Related]
3. Functional neuroimaging and electrophysiology biomarkers for clinical trials for cognition in schizophrenia.
Cho RY; Ford JM; Krystal JH; Laruelle M; Cuthbert B; Carter CS
Schizophr Bull; 2005 Oct; 31(4):865-9. PubMed ID: 16166611
[TBL] [Abstract][Full Text] [Related]
4. Drug initiatives to improve cognitive function.
Marder SR
J Clin Psychiatry; 2006; 67 Suppl 9():31-5; discussion 36-42. PubMed ID: 16965187
[TBL] [Abstract][Full Text] [Related]
5. A collaborative approach to targeted treatment development for schizophrenia: a qualitative evaluation of the NIMH-MATRICS project.
Bromley E
Schizophr Bull; 2005 Oct; 31(4):954-61. PubMed ID: 16166607
[TBL] [Abstract][Full Text] [Related]
6. Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia.
Carter CS
Schizophr Bull; 2005 Oct; 31(4):810-5. PubMed ID: 16107584
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. Distinguishing separable domains of cognition in human and animal studies: what separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the measurement and treatment research to improve cognition in schizophrenia new approaches conference.
Nuechterlein KH; Robbins TW; Einat H
Schizophr Bull; 2005 Oct; 31(4):870-4. PubMed ID: 16150960
[TBL] [Abstract][Full Text] [Related]
9. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
[TBL] [Abstract][Full Text] [Related]
10. Social cognition in schizophrenia: recommendations from the measurement and treatment research to improve cognition in schizophrenia new approaches conference.
Green MF; Olivier B; Crawley JN; Penn DL; Silverstein S
Schizophr Bull; 2005 Oct; 31(4):882-7. PubMed ID: 16135561
[TBL] [Abstract][Full Text] [Related]
11. Predicting drug efficacy for cognitive deficits in schizophrenia.
Hagan JJ; Jones DN
Schizophr Bull; 2005 Oct; 31(4):830-53. PubMed ID: 16177277
[TBL] [Abstract][Full Text] [Related]
12. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.
Green MF; Nuechterlein KH; Gold JM; Barch DM; Cohen J; Essock S; Fenton WS; Frese F; Goldberg TE; Heaton RK; Keefe RS; Kern RS; Kraemer H; Stover E; Weinberger DR; Zalcman S; Marder SR
Biol Psychiatry; 2004 Sep; 56(5):301-7. PubMed ID: 15336511
[TBL] [Abstract][Full Text] [Related]
13. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
14. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
[TBL] [Abstract][Full Text] [Related]
15. How should DSM-V criteria for schizophrenia include cognitive impairment?
Keefe RS; Fenton WS
Schizophr Bull; 2007 Jul; 33(4):912-20. PubMed ID: 17567627
[TBL] [Abstract][Full Text] [Related]
16. Treatment of cognitive dysfunction in schizophrenia.
Peuskens J; Demily C; Thibaut F
Clin Ther; 2005; 27 Suppl A():S25-37. PubMed ID: 16198199
[TBL] [Abstract][Full Text] [Related]
17. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
[TBL] [Abstract][Full Text] [Related]
18. Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic.
Day M; Balci F; Wan HI; Fox GB; Rutkowski JL; Feuerstein G
Curr Opin Investig Drugs; 2008 Jul; 9(7):696-706. PubMed ID: 18600575
[TBL] [Abstract][Full Text] [Related]
19. [Approaches to the development of the Japanese academic version of the MATRICS Consensus Cognitive Battery].
Sato T; Sora I
Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Nov; 31(5-6):241-4. PubMed ID: 22256613
[TBL] [Abstract][Full Text] [Related]
20. Treatment of cognitive deficits in schizophrenia.
Bowie CR; Harvey PD
Curr Opin Investig Drugs; 2006 Jul; 7(7):608-13. PubMed ID: 16869112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
